Sukhmani K. Padda was named director of Thoracic Medical Oncology at Cedars-Sinai Cancer.
Amy Jo Jenkins was named director of the Winthrop P. Rockefeller Cancer Institute’s new Office of Clinical Trials Administration and will lead early phase clinical trials at the University of Arkansas for Medical Sciences.
Andrew Schaefer, the Noah Harding Chair and a professor of computational and applied mathematics and computer science at Rice’s Brown School of Engineering, has received a four-year NCI grant for $1.2 million to develop a personalized approach to adaptive radiation therapy for head and neck cancers.
The American Red Cross and the American Cancer Society are collaborating to encourage people to donate blood for cancer treatment.
Results from the OlympiA Phase III trial showed olaparib (Lynparza) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival versus placebo in the adjuvant treatment of patients with germline BRCA-mutated high-risk human epidermal growth factor receptor 2-negative early breast cancer.
In a presentation of real-world data, researchers from Fox Chase Cancer Center have concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to receive second-line immunotherapy.
Cancer patients and survivors continue to deal with the negative effects of the coronavirus pandemic on their ability to access necessary health care.
A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study to be presented June 6 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children.
Truseltiq (Infigratinib) a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test.
